These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
114 related articles for article (PubMed ID: 11902118)
41. Flesinoxan dose-dependently reduces extracellular 5-hydroxytryptamine (5-HT) in rat median raphe and dorsal hippocampus through activation of 5-HT1A receptors. Bosker FJ; de Winter TY; Klompmakers AA; Westenberg HG J Neurochem; 1996 Jun; 66(6):2546-55. PubMed ID: 8632181 [TBL] [Abstract][Full Text] [Related]
42. PET imaging of brain 5-HT1A receptors in rat in vivo with 18F-FCWAY and improvement by successful inhibition of radioligand defluorination with miconazole. Tipre DN; Zoghbi SS; Liow JS; Green MV; Seidel J; Ichise M; Innis RB; Pike VW J Nucl Med; 2006 Feb; 47(2):345-53. PubMed ID: 16455642 [TBL] [Abstract][Full Text] [Related]
43. Effects of WAY 100635 and (-)-5-Me-8-OH-DPAT, a novel 5-HT1A receptor antagonist, on 8-OH-DPAT responses. Trillat AC; Malagié I; Mathé-Allainmat M; Anmela MC; Jacquot C; Langlois M; Gardier AM Eur J Pharmacol; 1998 Apr; 347(1):41-9. PubMed ID: 9650846 [TBL] [Abstract][Full Text] [Related]
44. On the quantification of [18F]MPPF binding to 5-HT1A receptors in the human brain. Passchier J; van Waarde A; Vaalburg W; Willemsen AT J Nucl Med; 2001 Jul; 42(7):1025-31. PubMed ID: 11438622 [TBL] [Abstract][Full Text] [Related]
46. Effect of chronic fluoxetine and WAY-100635 treatment on serotonergic neurotransmission in the frontal cortex. Dawson LA; Nguyen HQ; Smith DL; Schechter LE J Psychopharmacol; 2002 Jun; 16(2):145-52. PubMed ID: 12095073 [TBL] [Abstract][Full Text] [Related]
47. Effects of 5-HT1A receptor antagonists on hippocampal 5-hydroxytryptamine levels: (S)-WAY100135, but not WAY100635, has partial agonist properties. Assié MB; Koek W Eur J Pharmacol; 1996 May; 304(1-3):15-21. PubMed ID: 8813579 [TBL] [Abstract][Full Text] [Related]
48. Functional effects of chronic electroconvulsive shock on serotonergic 5-HT(1A) and 5-HT(1B) receptor activity in rat hippocampus and hypothalamus. Gur E; Dremencov E; Garcia F; Van de Kar LD; Lerer B; Newman ME Brain Res; 2002 Oct; 952(1):52-60. PubMed ID: 12363404 [TBL] [Abstract][Full Text] [Related]
49. A 18F-MPPF PET normative database of 5-HT1A receptor binding in men and women over aging. Costes N; Merlet I; Ostrowsky K; Faillenot I; Lavenne F; Zimmer L; Ryvlin P; Le Bars D J Nucl Med; 2005 Dec; 46(12):1980-9. PubMed ID: 16330560 [TBL] [Abstract][Full Text] [Related]
50. Effects of co-administration of a monoamine oxidase inhibitor and a 5-HT1A receptor antagonist on 5-hydroxytryptamine cell firing and release. Sharp T; Gartside SE; Umbers V Eur J Pharmacol; 1997 Feb; 320(1):15-9. PubMed ID: 9049597 [TBL] [Abstract][Full Text] [Related]
51. Differential effects of coadministration of fluoxetine and WAY-100635 on serotonergic neurotransmission in vivo: sensitivity to sequence of injections. Taber MT; Kinney GG; Pieschl RL; Yocca FD; Gribkoff VK Synapse; 2000 Oct; 38(1):17-26. PubMed ID: 10941137 [TBL] [Abstract][Full Text] [Related]
53. WAY-100635 antagonist-induced plasticity of 5-HT receptors: regulatory differences between a stable cell line and an in vivo native system. Khawaja XZ; Smith DL; Nawoschik SP; Zhang J; Dunlop J; Dilks DW; Olsen M; Schechter LE J Neurochem; 2006 Jul; 98(1):134-45. PubMed ID: 16805803 [TBL] [Abstract][Full Text] [Related]
54. Effects of repeated systemic administration of d-Fenfluramine on serotonin and glutamate release in rat ventral hippocampus: comparison with methamphetamine using in vivo microdialysis. Rocher C; Gardier AM Naunyn Schmiedebergs Arch Pharmacol; 2001 Apr; 363(4):422-8. PubMed ID: 11330336 [TBL] [Abstract][Full Text] [Related]
55. Quantitative imaging of 5-HT(1A) receptor binding in healthy volunteers with [(18)f]p-MPPF. Passchier J; van Waarde A; Pieterman RM; Elsinga PH; Pruim J; Hendrikse HN; Willemsen AT; Vaalburg W Nucl Med Biol; 2000 Jul; 27(5):473-6. PubMed ID: 10962253 [TBL] [Abstract][Full Text] [Related]
56. Effect of a 5-HT(1A) receptor agonist, flesinoxan, on the extracellular noradrenaline level in the hippocampus and on the locomotor activity of rats. Suwabe A; Kubota M; Niwa M; Kobayashi K; Kanba S Brain Res; 2000 Mar; 858(2):393-401. PubMed ID: 10708692 [TBL] [Abstract][Full Text] [Related]
57. [(18)F]p-MPPF: aA radiolabeled antagonist for the study of 5-HT(1A) receptors with PET. Plenevaux A; Lemaire C; Aerts J; Lacan G; Rubins D; Melega WP; Brihaye C; Degueldre C; Fuchs S; Salmon E; Maquet P; Laureys S; Damhaut P; Weissmann D; Le Bars D; Pujol JF; Luxen A Nucl Med Biol; 2000 Jul; 27(5):467-71. PubMed ID: 10962252 [TBL] [Abstract][Full Text] [Related]
58. [18F]fluoroalkyl analogues of the potent 5-HT1A antagonist WAY 100635: radiosyntheses and in vivo evaluation. Wilson AA; DaSilva JN; Houle S Nucl Med Biol; 1996 May; 23(4):487-90. PubMed ID: 8832704 [TBL] [Abstract][Full Text] [Related]
59. 5-HT4 receptor-mediated modulation of 5-HT release in the rat hippocampus in vivo. Ge J; Barnes NM Br J Pharmacol; 1996 Apr; 117(7):1475-80. PubMed ID: 8730742 [TBL] [Abstract][Full Text] [Related]